Get to know more about us
We are transforming the landscape of Ai drug discovery through the integration of artificial intelligence and multi-omic data analysis.
Get to know more about us
We are transforming the landscape of Ai drug discovery through the integration of artificial intelligence and multi-omic data analysis.
Our Mission
EpigeNeuro.AI is dedicated to transforming the landscape of drug discovery by leveraging artificial intelligence and multi-omic data integration. Our mission is to accelerate the identification of gene targets to slow down aging and the progression of age-related diseases.
Our Story
EpigeNeuro.AI was born out of a need to address the inefficiencies in traditional drug discovery processes. With a vision to revolutionize the field, we have combined cutting-edge AI technology with comprehensive multi-omic data analysis to offer a unique solution to the challenges of aging and age-related diseases.
About the founder
As EpigeNeuroAI’s Co-founder and CEO, Samuel builds on over a decade of academic and professional career in Computing – with a specific focus on using digital transformation tools, including Artificial Intelligence, to drive innovation in Healthcare. Prior to founding EpigeNeuroAI, Samuel was a Digital Health Specialist at the Solina Center for International Development and Research – one of the leading health consulting firms that works with large donor funders like the Bill Gates Foundation & USAID to address pressing healthcare problems in Africa. There he led several digital health initiatives that positively affected more than 400,000 lives. Additionally, he led several corporate business development, product management, clinical decision support systems development, as well as program management operations.
The birth of EpigeNeuroAI came from Samuel’s research work in Biomedicine during his Master’s program at Iowa State University’s Department of Computer Science – where his work focused on the intersection of Artificial Intelligence with the use of next-generation sequencing technologies in the study of age-related neurodegenerative diseases such as cancer. Furthermore, he developed a diagnostic tool that leveraged Computer Vision in Artificial Intelligence to provide a trustworthy and safe diagnosis in Cellular Biology, which has informed one of the trademark products at EpigeNeuroAI – the EpigeNeuroAI-Vision.
Samuel holds a Bachelor of Engineering in Computer Engineering (Digital Health focus) from the Federal University Oye-Ekiti, Nigeria. Additionally, he holds two Master’s degrees – in Computer Science; and Artificial Intelligence – from Iowa State University, USA, along with an MBA from the Quantic School of Business and Technology, USA.
About the founder
